Online citations, reference lists, and bibliographies.
← Back to Search

Background Parenchymal Enhancement And Fibroglandular Tissue Proportion On Breast MRI: Correlation With Hormone Receptor Expression And Molecular Subtypes Of Breast Cancer.

M. Öztürk, A. Polat, Yurdanur Süllü, L. Tomak, Ayfer Kamali Polat
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To assess the relationship between background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) proportion on breast magnetic resonance imaging (MRI) and hormone receptor expression and molecular subtypes in invasive breast cancer. MATERIALS AND METHODS This retrospective study enrolled 75 breast cancer patients who underwent breast MRI before treatment. T1-weighted images were reviewed to determine the FGT proportion, and contrast-enhanced fat-suppressed T1-weighted images were reviewed to determine BPE. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2-neu (HER2) status, and molecular subtypes of the tumors were compared with the BPE and FGT proportions. RESULTS Women with high BPE tended to have increased rate of ER and PR positive tumors (p=0.018 and p=0.013). FGT proportion was associated with ER positivity (p=0.009), but no significant differences between FGT proportion and PR positivity were found (p=0.256). There was no significant difference between HER2 status and any of the imaging features (p=0.453 and p=0.922). For premenopausal women, both FGT proportion and BPE were associated with molecular subtypes (p=0.025 and p=0.042). FGT proportion was also associated with BPE (p<0.001). CONCLUSION In women with invasive breast cancer, both high FGT containing breasts and high BPE breasts tended to have ER positive tumors.
This paper references
10.1007/s10552-010-9709-0
Reproductive history and risk of three breast cancer subtypes defined by three biomarkers
A. Phipps (2010)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1016/j.canep.2010.11.011
Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study.
S. Conroy (2011)
10.1016/J.RCL.2007.07.002
Diagnostic breast MR imaging: current status and future directions.
E. Morris (2007)
10.1007/s10552-006-0071-1
Breast cancer risk factors in relation to breast density (United States)
L. Titus-Ernstoff (2006)
10.1016/j.crad.2015.02.017
Background parenchymal enhancement on breast MRI and mammographic breast density: correlation with tumour characteristics.
M. Kim (2015)
10.1093/annonc/mdq754
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
S. Aebi (2011)
10.1200/JCO.2009.25.6529
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M. Hammond (2010)
10.1148/RADIOLOGY.203.1.9122383
Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast.
M. Müller-Schimpfle (1997)
Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?
J. Potter (1995)
10.1148/radiol.14132641
Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
M. Mazurowski (2014)
10.1002/1097-0142(19910601)67:11<2833::AID-CNCR2820671121>3.0.CO;2-U
Mammographic densities and risk of breast cancer
A. Saftlas (1991)
10.1007/s10552-006-0073-z
Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States)
E. Aiello (2006)
10.1111/j.1524-4741.2010.00907.x
Mammographic Density, Estrogen Receptor Status and Other Breast Cancer Tumor Characteristics
Jane Ding (2010)
10.1093/JNCI/95.1.30
Postmenopausal hormone therapy and change in mammographic density.
G. Greendale (2003)
Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup.
M. Cotterchio (2003)
10.1200/JCO.2013.50.9984
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
A. Wolff (2013)
10.1148/radiol.11102156
Background parenchymal enhancement at breast MR imaging and breast cancer risk.
Valencia King (2011)
10.1148/radiol.12112590
Normal breast parenchyma: contrast enhancement kinetics at dynamic MR mammography--influence of anthropometric measures and menopausal status.
K. Hegenscheid (2013)
10.1016/j.ejrad.2011.04.059
Should breast MRI be performed with adjustment for the phase in patients' menstrual cycle? Correlation between mammographic density, age, and background enhancement on breast MRI without adjusting for the phase in patients' menstrual cycle.
T. Uematsu (2012)
10.1148/RADIOLOGY.203.1.9122382
Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency.
C. Kuhl (1997)
10.1016/j.ijrobp.2009.04.059
The association between biological subtype and isolated regional nodal failure after breast-conserving therapy.
Jennifer Y. Wo (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar